Overview

Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

Status:
Withdrawn

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

We hope to learn more about the clinical efficacy of bortezomib in T-cell prolymphocytic leukemia. Patients will be selected as a possible participant in this study because they have a bone marrow disorder known as T-cell prolymphocytic leukemia (T-cell PLL) which does not tend to respond well to conventional treatment with chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Stanford University

Collaborator:

Millennium Pharmaceuticals, Inc.

Treatments:

Bortezomib